Jamroziak, K., Iskierka-Jazdzewska, E., Robak, T., Zielonka, K., Giebel, S., Wisniewski, K., Drozd-Sokolowska, J., Rybka, J., Piszczek, W., Joks, M., Dabrowska-Iwanicka, A., Mital, A., Steckiewicz, P., Lech-Maranda, E., Jasinski, M., Rymko, M., Marciniak, D., Wróbel, T., Gil, L., Romejko-Jarosińska, J., Kruk-Kwapisz, D., Chudy, A., Machnicki, M., Giannopoulos, K., Stoklosa, T., Górecki, T., Pula, B. (2025). Minimal residual disease-guided venetoclax plus rituximab for patients with previously untreated chronic lymphocytic leukemia (VERITA PALG-CLL5): primary endpoint analysis of the prospective, multicenter, Phase 2 trial. Blood. https://doi.org/10.1182/blood-2025-5675